[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100358030":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":42,"centralContacts":20,"locations":46,"responsibleParty":69,"collaborators":71,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":20,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":20,"enrollmentInfo":84,"targetDuration":20,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":20,"overallStatus":49,"whyStopped":20,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Group I (LVB)","EXPERIMENTAL","Patients receive indocyanine green IV and undergo lymphangiography, then undergo LVB at the time of ALND.",[13,14,15],"Drug: Indocyanine Green","Procedure: Lymphangiography","Procedure: Lymphovenous Bypass",{"label":17,"type":18,"description":19,"interventionNames":20},"Group II (no intervention)","NO_INTERVENTION","Patients do not receive indocyanine green, undergo lymphangiography, nor undergo LVB at the time of ALND.",null,[22,29,36],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Indocyanine Green","Given IV",[9],[28],"ICG",{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"PROCEDURE","Lymphangiography","Undergo lymphangiography",[9],[35],"Lymphography",{"type":30,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"Lymphovenous Bypass","Undergo LVB",[9],[41],"Lymphovenous Anastomosis",[43],{"name":44,"affiliation":5,"role":45},"Mark Schaverien","PRINCIPAL_INVESTIGATOR",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"M D Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-95.36327,29.76328,{"lat":59,"lon":58},[62,66,68],{"name":44,"role":63,"phone":64,"phoneExt":20,"email":65},"CONTACT","832-499-6321","sehull@mdanderson.org",{"name":67,"role":63,"phone":64,"phoneExt":20,"email":65},"Sara Hull, BSN,MHA,RN",{"name":44,"role":45,"phone":20,"phoneExt":20,"email":20},{"type":70,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[72],{"name":73,"class":74},"National Cancer Institute (NCI)","NIH","100358030","lymphovenous-bypass-procedure-before-underarm-lymph-node-surgery-in-preventing-lymphedema-in-patients-with-inflammatory-or-locally-advanced-non-inflammatory-breast-cancer-or-melanoma-100358030",false,"NCT03941756","Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma","Prophylactic Lymphovenous Bypass Procedure Following Axillary Lymphadenectomy: A Prospective Observational Study","Inclusion Criteria:\n\n* Patients greater than or equal to 18 years of age.\n* Patients willing to participate.\n* Patients able to complete informed consent.\n* Patients will be eligible for inclusion if they fall into one for two groups:\n\n  * Patients with inflammatory breast cancer, and those with locally advanced non-inflammatory breast cancer that are undergoing ALND and are anticipated to receive radiation therapy\n  * Or: Patients with a diagnosis of melanoma (including unknown primary) that will undergo ALND will also be eligible for inclusion in the study as a comparator group.\n\nExclusion Criteria:\n\n* Patients taking anticoagulants within 7 days prior to surgery.\n* Patients that are known to be pregnant at the time of surgery.\n* Patients are available for follow-up less than 18 months or do not undergo measurements within the scheduled period.\n* Patients with body mass index (BMI) greater than 50.0.","ALL","18 Years",{"count":85,"type":86},252,"ESTIMATED","INTERVENTIONAL",[89],"NA","This pilot trial studies whether a procedure called lymphovenous bypass would prevent lymphedema (arm swelling) in patients with inflammatory breast cancer or non-inflammatory breast cancer that has spread to nearby tissues or lymph nodes or melanoma. The lymphovenous bypass procedure creates a path for lymphatic fluid to flow away from the arms. It is usually done after a diagnosis of lymphedema. In this study, giving lymphovenous bypass before underarm lymph node surgery may help prevent lymphedema from forming.",[92,93,94,95],"Anatomic Stage III Breast Cancer AJCC v8","Breast Inflammatory Carcinoma","Locally Advanced Breast Carcinoma","Melanoma","2026-05-22",{"date":98,"type":99},"2026-05-26","ACTUAL",{"date":101,"type":99},"2018-08-14",{"date":103,"type":86},"2027-12-01",{"name":5,"class":6},1]